- Home
- WBS vs JAZZ Comparison
WBS vs JAZZ Comparison
Compare WBS & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WBS
- JAZZ
- Stock Information
- Founded
- WBS 1935
- JAZZ 2003
- Country
- WBS United States
- JAZZ Ireland
- Employees
- WBS N/A
- JAZZ N/A
- Industry
- WBS Major Banks
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- WBS Finance
- JAZZ Health Care
- Exchange
- WBS Nasdaq
- JAZZ Nasdaq
- Market Cap
- WBS 9.9B
- JAZZ 8.2B
- IPO Year
- WBS N/A
- JAZZ 2007
- Fundamental
- Price
- WBS $57.75
- JAZZ $139.06
- Analyst Decision
- WBS Strong Buy
- JAZZ Strong Buy
- Analyst Count
- WBS 14
- JAZZ 14
- Target Price
- WBS $70.77
- JAZZ $179.43
- AVG Volume (30 Days)
- WBS 1.7M
- JAZZ 553.4K
- Earning Date
- WBS 10-17-2025
- JAZZ 11-05-2025
- Dividend Yield
- WBS 2.81%
- JAZZ N/A
- EPS Growth
- WBS 21.39
- JAZZ N/A
- EPS
- WBS 5.36
- JAZZ N/A
- Revenue
- WBS $2,581,185,000.00
- JAZZ $4,086,695,000.00
- Revenue This Year
- WBS $8.80
- JAZZ $5.75
- Revenue Next Year
- WBS $3.65
- JAZZ $6.09
- P/E Ratio
- WBS $10.61
- JAZZ N/A
- Revenue Growth
- WBS 8.96
- JAZZ 4.52
- 52 Week Low
- WBS $39.43
- JAZZ $95.49
- 52 Week High
- WBS $63.99
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- WBS 47.48
- JAZZ 54.13
- Support Level
- WBS $55.63
- JAZZ $133.45
- Resistance Level
- WBS $57.05
- JAZZ $139.07
- Average True Range (ATR)
- WBS 1.25
- JAZZ 3.16
- MACD
- WBS 0.19
- JAZZ -0.43
- Stochastic Oscillator
- WBS 84.44
- JAZZ 53.87
About WBS Webster Financial Corporation
Webster Financial Corp is a full-service provider of financial services, offering commercial and consumer banking, mortgages, and investment advisory along with trust and wealth management services in Connecticut, New York, Rhode Island, Massachusetts, and Pennsylvania. The company's segment includes Commercial Banking, HSA Bank, and Consumer Banking. It generates maximum revenue from the Commercial Banking segment.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.